Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials
Scheduled presentations are now listed on the Biotech Showcase website. Thanks in advance to noretreat (and others?) who may be attending.
Resverlogix Monday January 7, 4 PM Pacific
Zenith Epigenetics Tuesday January 8th, 9:15 AM Pacific